Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lang

Showing results (251-260 of 312) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trialPeter Bader, Hermann Kreyenberg, Arend von Stackelberg, et al.
Oncotarget|November 9, 2016
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cellsChristian B Schiller, Todd A Braciak, Nadja C Fenn, et al.
Bone Marrow Transplantation|March 5, 2020
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)Bruce Morland, Tomas Kepak, Sandro Dallorso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?Peter Bader, Hermann Kreyenberg, Walter Hoelle, et al.
Cancer Immunology, Immunotherapy : CII|January 19, 2024
Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 7, 2016
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 AntibodyUrsula Jördis Eva Seidel, Patrick Schlegel, Ludger Grosse-Hovest, et al.
Blood|January 25, 2015
Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCTJudith Feucht, Kathrin Opherk, Peter Lang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016Monzr M Al Malki, Richard Jones, Qing Ma, et al.
British Journal of Haematology|December 6, 2017
CD34<sup>+</sup> selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantationChiara Mainardi, Martin Ebinger, Sigrid Enkel, et al.
Frontiers in Oncology|May 27, 2022
No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care TherapySebastian Johannes Schober, Erika Hallmen, Florian Reßle, et al.
Pageof 32

Showing results (251-260 of 312) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trialPeter Bader, Hermann Kreyenberg, Arend von Stackelberg, et al.
Oncotarget|November 9, 2016
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cellsChristian B Schiller, Todd A Braciak, Nadja C Fenn, et al.
Bone Marrow Transplantation|March 5, 2020
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)Bruce Morland, Tomas Kepak, Sandro Dallorso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?Peter Bader, Hermann Kreyenberg, Walter Hoelle, et al.
Cancer Immunology, Immunotherapy : CII|January 19, 2024
Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 7, 2016
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 AntibodyUrsula Jördis Eva Seidel, Patrick Schlegel, Ludger Grosse-Hovest, et al.
Blood|January 25, 2015
Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCTJudith Feucht, Kathrin Opherk, Peter Lang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016Monzr M Al Malki, Richard Jones, Qing Ma, et al.
British Journal of Haematology|December 6, 2017
CD34<sup>+</sup> selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantationChiara Mainardi, Martin Ebinger, Sigrid Enkel, et al.
Frontiers in Oncology|May 27, 2022
No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care TherapySebastian Johannes Schober, Erika Hallmen, Florian Reßle, et al.
Pageof 32